Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - OxySure Therapeutics, Inc. | f8k090414ex99i_oxysure.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 10, 2014 (September 4, 2014)
OxySure Systems, Inc.
(Exact name of registrant as specified in its chapter)
| Delaware | 000-54137 | 71-0960725 | ||
| (State or other jurisdiction of incorporation |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
| 10880 John W. Elliott Drive, Suite 600, Frisco, TX | 75033 | |
| (Address of principal executive offices) | (Zip Code) |
(972) 294-6450
Registrant's telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 1 – Registrant’s Business and Operations
Item 1.01 – Entry into a Material Definitive Agreement.
On September 9, 2014, OxySure Systems, Inc. (the “Company”) issued a press release regarding its entry into a distribution contract with Ajad Medical in the Kingdom of Saudi Arabia. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in Item 1.01 of this report, including the press release attached as Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, such information shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Press release dated September 9, 2014 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 10, 2014 | ||
| OXYSURE SYSTEMS, INC., | ||
| a Delaware corporation | ||
| /s/ Julian T. Ross | ||
| BY: | Julian T. Ross | |
| ITS: | Chief Executive Officer, President, | |
| Chief Financial Officer, and Secretary | ||
3